Can ferric citrate lead to iron overload in peritoneal dialysis patients?
.

Author: AslamNabeel, BasdeoLuke M, GovaniMaulik, WadeiHani M

Paper Details 
Original Abstract of the Article :
Ferric citrate (FC), a novel oral phosphate binder, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients receiving dialysis. FC binds to dietary phosphate in the gastrointestinal (GI) tract producing ferric phosp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.5414/CN109738

データ提供:米国国立医学図書館(NLM)

Ferric Citrate: A Hidden Oasis in the Desert of Dialysis

Peritoneal dialysis, a life-sustaining treatment for end-stage renal disease (ESRD), presents a complex landscape for managing mineral imbalances. Ferric citrate (FC), a novel oral phosphate binder, has emerged as a promising tool for controlling hyperphosphatemia in these patients. However, the authors of this study raise concerns about the potential for iron overload when using FC in peritoneal dialysis (PD) patients.

They present three cases of PD patients who developed iron overload while receiving FC, highlighting the need for careful monitoring of iron levels and potentially adjusting the maximum approved dose in this population. The study underscores the importance of a vigilant approach to managing iron levels in PD patients receiving FC therapy.

Iron Overload: A Hidden Danger in the Desert

The desert can be a deceptive landscape, where seemingly benign elements can pose hidden dangers. Similarly, iron overload, like a subtle shift in the desert's ecosystem, can have significant health consequences. This study emphasizes the importance of a watchful eye for potential complications associated with FC therapy, particularly in PD patients.

Managing Iron Levels: Navigating a Desert Oasis

Peritoneal dialysis, like a delicate oasis in the desert, requires careful management to maintain a healthy balance. This study underscores the importance of monitoring iron levels in PD patients receiving FC therapy, emphasizing the need for a vigilant approach to prevent iron overload and ensure optimal patient outcomes. By closely monitoring iron levels and adjusting therapy as needed, healthcare professionals can guide patients through this challenging terrain towards a healthier future.

Dr. Camel's Conclusion

This study highlights the importance of vigilant monitoring and potentially adjusting the maximum approved dose of FC in peritoneal dialysis patients. Iron overload, like a hidden danger in the desert, can have significant consequences for these patients. By carefully managing iron levels and employing a collaborative approach to patient care, healthcare professionals can ensure the safety and effectiveness of FC therapy in this complex patient population.

Date :
  1. Date Completed 2020-09-02
  2. Date Revised 2020-09-02
Further Info :

Pubmed ID

31933474

DOI: Digital Object Identifier

10.5414/CN109738

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.